Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3213179 | 1.00 | MEN1 (0.55) | MEN1KMT2A | |
| SCHEMBL13491780 | 0.89 | GAA (0.56) | — | |
| SCHEMBL13491830 | 0.88 | MEN1 (0.52) | MEN1KMT2A | |
| SCHEMBL7965807 | 0.88 | GAA (0.64) | — | |
| SCHEMBL7961631 | 0.85 | MEN1 (0.51) | MEN1KMT2A | |
| SCHEMBL7965804 | 0.84 | GAA (0.51) | — | |
| SCHEMBL19416801 | 0.84 | GAA (0.55) | MEN1KMT2A | |
| SCHEMBL13491767 | 0.84 | — | — | |
| SCHEMBL13491835 | 0.82 | ABCG2 (0.46) | MEN1KMT2A | |
| SCHEMBL7967230 | 0.82 | MAPT (0.51) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783521-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2310016-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20140038951-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2014-02-06 | — | — | US | disclosed |
| US-8377930-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100035872-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038951-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | MEN1 3291/4885KMT2A 2449/4885 |
| US-20100035872-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | MEN1 3291/4885KMT2A 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.